Subscribe To
Regeneron reports third quarter 2023 financial and operating results
Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022 Third quarter 2023 Dupixent® global net sales (recorded by Sanof...
November 2, 2023, 10:30 am
Regeneron beats quarterly profit estimates on eczema treatment strength
Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent....
November 2, 2023, 6:42 am
Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...
October 22, 2023, 6:59 pm
Fda accepts sanofi's (sny) sbla for dupixent in pediatric eoe
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) dupixent will be the first FDA-approved tre...
September 26, 2023, 9:46 am
Dupixent® (dupilumab) sbla for treatment of eosinophilic esophagitis (eoe) in children aged 1 to 11 accepted for fda priority review
If approved, dupixent would be the first and only treatment in the U.S. indicated for children aged 1 t...
September 26, 2023, 5:29 am
Sanofi: 3 reasons for a buy
The French Pharma company is moving on an immunology franchise. dupixent is the internal cash cow to dr...
September 21, 2023, 9:26 am
An old dog with a new trick… ellodi’s apt-1011 promises eoe patients a convenient and potent treatment alternative
Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE treatment gold standard, Dupixe...
August 15, 2023, 7:40 pm
Regeneron (regn) q2 earnings & sales top, eylea sales decline
Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet aga...
August 3, 2023, 2:15 pm
Regeneron pharma beats profit estimates on dupixent demand
Regeneron Pharmaceuticals Inc beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for eczema treatment Dupixent....
August 3, 2023, 6:37 am
Regeneron (regn) to report q2 earnings: what's in store?
Investors' focus is likely to be on the performance of lead drugs Eylea and dupixent when Regeneron (RE...
July 28, 2023, 2:00 pm
Sanofi lifts earnings outlook on dupixent sales, new drug launches
French drugmaker Sanofi on Friday increased its guidance for full-year earnings on strong sales of anti-inflammatory treatment ...
July 28, 2023, 1:42 am
Regeneron: solid investment based on continued eylea expansion
Regeneron Pharmaceuticals, Inc. has potential to receive FDA approval of higher dosing of 8 mg of EYLEA, which has been set with an FDA target action ...
June 13, 2023, 5:55 pm
Sanofi: smoker's lung drug benefit was swift and sustained in trial
The benefits of Sanofi and Regeneron's anti-inflammatory drug dupixent set in quickly during a trial to...
May 22, 2023, 2:20 am
Dupixent® (dupilumab) late-breaking phase 3 copd results presented at ats and simultaneously published in the new england journal of medicine
dupixent is the first and only investigational biologic for COPD that has demonstrated a significant re...
May 21, 2023, 6:18 pm
Regeneron (regn) faces challenges as eylea sales decline
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, dupixent ...
May 19, 2023, 3:18 pm
Is a beat on the cards for regeneron's (regn) q1 earnings?
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent....
May 1, 2023, 9:09 am
Sanofi (sny) q1 earnings beat, sales miss, dupixent strong
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of dupixen...
April 27, 2023, 12:10 pm
Verona pharma: ensifentrine vs. dupixent, ensifentrine is a breath of fresh air
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air...
April 16, 2023, 1:22 am
Regeneron: new highs following dupixent's copd data
Shares of Regeneron jumped to new all-time highs following the successful phase 3 results of dupixent i...
April 13, 2023, 6:12 am
Is this pharma duo on the brink of another billion-dollar opportunity?
Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medi...
March 30, 2023, 5:48 am